Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Psilocybin narrowly beat Lexapro in small depression study

By Brian Buntz | April 16, 2021

Psilocybin mushrooms

Image courtesy of Wikipedia

The magic mushroom compound psilocybin appeared to be slightly more effective than the selective serotonin-reuptake inhibitor escitalopram (Lexapro) in a small study recently published in NEJM.  

In the Phase 2 study, which tracked 59 patients over six weeks, the psilocybin group had an approximately 8-point average drop in the Quick Inventory of Depressive Symptomatology (Self-Report) questionnaire with 16 questions (QIDS-SR16). The 29 patients had a 6-point reduction on the 27-point scale. Higher scores on the scale correlate to more severe depression. 

The researchers concluded that there was not “a significant difference in antidepressant effects between psilocybin and escitalopram” in the study. Secondary outcomes, however, tended to favor psilocybin over escitalopram. The researchers added that more studies are needed to evaluate psilocybin against conventional antidepressants. 

The study was performed at Imperial College London.

Another paper in NEJM concluded that care is needed when interpreting the study results. “Heterogeneity among patients, who volunteered for the trial in response to advertisements, and uncertainty regarding the appropriate therapeutic dose range and frequency of administration of psilocybin may have influenced the results,” concluded psychiatrist Dr. Jeffrey A. Lieberman.

One point of note regarding the Phase 2 trial is the fact that both groups received psilocybin. The first group received two 25-mg doses of psilocybin three weeks apart and six weeks of daily placebo pills. The second group received daily escitalopram. That placebo group also received two 1-mg doses of psilocybin at the same interval as the first cohort. 

Both cohorts were told they would receive psilocybin.

Both groups received psychological support. 

Psilocybin is not generally considered psychoactive at doses of less than 3 mg, according to the Drug Policy Alliance. In research settings, psilocybin dosing is typically in the range of 14–30 mg. 

Escitalopram can take as long as four to six weeks to begin having a full effect on patients. 

Several companies have explored the use of psychedelics in clinical trials to treat conditions ranging from treatment-resistant depression and post-traumatic stress disorder to opioid- and alcohol-use disorders. 

Usona Institute, for instance, is also investigating the use of psilocybin to treat major depressive disorder. 

The mechanism of how psilocybin and other psychedelics can treat depression is unclear. 

In general, researchers have ramped up studies on psychedelic drugs in the past decade, testing their potential to treat depression, anxiety and other conditions.

Researchers are also developing compounds derived from psychedelics designed to have a pharmacologic but not mind-altering influence.


Filed Under: clinical trials, Drug Discovery
Tagged With: depression, escitalopram, Lexapro, psilocybin
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE